Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

This study has been completed.

Sponsor:

Information provided by:

Asociación para Evitar la Ceguera en México

ClinicalTrials.gov Identifier:

NCT00407121

First received: December 1, 2006

Last updated: NA

Last verified: December 2006

History: No changes posted

Purpose

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Condition	Intervention	Phase
Vogt Koyanagi Harada Disease Serpiginous Choroiditis Multifocal Choroiditis	Drug: Bevacizumab Procedure: Intravitreal Injection of Bevacizumab	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Resource links provided by NLM:

Drug Information available for: Bevacizumab

Genetic and Rare Diseases Information Center resources: Chorioretinitis Choroiditis Multifocal Choroiditis Panuveitis Posterior Uveitis Serpiginous Choroiditis Vogt-Koyanagi-Harada Disease

U.S. FDA Resources

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:

Best corrected visual acuity
Retinal thickness by OCT
Leakage in Fluorescein angiogram


Study Start Date:	August 2006
Estimated Study Completion Date:	November 2006

Eligibility


Ages Eligible for Study:	25 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Clinical Diagnose
Patient Consent
Chronic stage of inflammation

Exclusion Criteria:

only eye
age lower than 30 yo.
Systemic condition

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00407121

Locations


Mexico
Asociacion para Evitar la Ceguera en Mexico
Mexico, Distrito Federal, Mexico, 04030

Sponsors and Collaborators

Asociación para Evitar la Ceguera en México

Investigators


Principal Investigator:	Veronica Kon-Jara, MD	Asociación para Evitar la Ceguera en México
Study Chair:	LuzElena Concha-Del Rio, MD	Asociación para Evitar la Ceguera en México

More Information

No publications provided


ClinicalTrials.gov Identifier:	NCT00407121 History of Changes
Other Study ID Numbers:	APEC-0025
Study First Received:	December 1, 2006
Last Updated:	December 1, 2006
Health Authority:	National Institute of Public Health: Health Secretariat

Keywords provided by Asociación para Evitar la Ceguera en México:


Neovascular Membrane Uveitis Bevacizumab

Additional relevant MeSH terms:


Choroiditis Uveomeningoencephalitic Syndrome Autoimmune Diseases Autoimmune Diseases of the Nervous System Central Nervous System Diseases Central Nervous System Infections Choroid Diseases Eye Diseases Immune System Diseases Meningoencephalitis Nervous System Diseases Panuveitis	Uveal Diseases Uveitis Uveitis, Posterior Bevacizumab Angiogenesis Inhibitors Angiogenesis Modulating Agents Antineoplastic Agents Growth Inhibitors Growth Substances Pharmacologic Actions Physiological Effects of Drugs Therapeutic Uses

ClinicalTrials.gov processed this record on March 02, 2015

To Top